Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 5, Pages 1745
Publisher
Baishideng Publishing Group Inc.
Online
2016-01-21
DOI
10.3748/wjg.v22.i5.1745
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer
- (2014) Wa Zhong et al. PATHOLOGY & ONCOLOGY RESEARCH
- Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer
- (2014) Clemens Giessen et al. TUMOR BIOLOGY
- Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
- (2014) Hui-Yan Luo WORLD JOURNAL OF GASTROENTEROLOGY
- Colorectal cancer surveillance: What's new and what's next
- (2014) Johnie Rose WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
- (2013) J M Jürgensmeier et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
- (2013) M.J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular Alterations and Biomarkers in Colorectal Cancer
- (2013) William M. Grady et al. TOXICOLOGIC PATHOLOGY
- Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells
- (2013) Russell C. Langan et al. Journal of Cancer
- Evaluation of predictive markers for patients with advanced colorectal cancer
- (2012) Per Byström et al. ACTA ONCOLOGICA
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
- (2012) X. Liao et al. CLINICAL CANCER RESEARCH
- Molecular Tests for Colorectal Cancer Screening
- (2012) Linda J.W. Bosch et al. Clinical Colorectal Cancer
- PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- (2012) Arjun Sood et al. Clinical Colorectal Cancer
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Ezrin expression in rectal cancer predicts time to development of local recurrence
- (2012) Fredrik Jörgren et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer
- (2012) Toshiaki Watanabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
- (2012) Mafalda M Dias et al. PHARMACOGENOMICS
- Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients
- (2011) Katerina Shulman et al. CANCER
- Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
- (2011) Timothy J. Price et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management
- (2011) Pragatheeshwar Thirunavukarasu et al. JNCI-Journal of the National Cancer Institute
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Ezrin Expression as a Prognostic Marker in Colorectal Adenocarcinoma
- (2011) Marcelo Patara et al. PATHOLOGY & ONCOLOGY RESEARCH
- Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
- (2010) R. Labianca et al. ANNALS OF ONCOLOGY
- Intensive Risk-Adjusted Follow-up With the CEA, TPA, CA19.9, and CA72.4 Tumor Marker Panel and Abdominal Ultrasonography to Diagnose Operable Colorectal Cancer Recurrences
- (2010) Andrea Nicolini ARCHIVES OF SURGERY
- Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening
- (2010) A. Link et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening
- (2010) Y. Koga et al. Cancer Prevention Research
- NRAS Mutations Are Rare in Colorectal Cancer
- (2010) Natsumi Irahara et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
- (2010) S. Tejpar et al. ONCOLOGIST
- Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals
- (2010) Hans J. Nielsen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- Clinical implications of microsatellite instability in sporadic colon cancers
- (2009) Frank A Sinicrope et al. CURRENT OPINION IN ONCOLOGY
- Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
- (2009) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia
- (2009) Takeshi Nagasaka et al. JNCI-Journal of the National Cancer Institute
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- Molecular Basis of Colorectal Cancer
- (2009) Sanford D. Markowitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
- (2008) E Rouits et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis
- (2008) Yoshikatsu Koga et al. CANCER SCIENCE
- Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients
- (2008) Frank Diehl et al. GASTROENTEROLOGY
- Quantitative Real-time RT-PCR Detection for Survivin, CK20 and CEA in Peripheral Blood of Colorectal Cancer Patients
- (2008) C. Shen et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention
- (2007) K. Koss et al. Colorectal Disease
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation